Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients

Status:	Active, not recruiting
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	August 2012
End Date:	September 2016

Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Liver Transplant Recipients

The main focus of this study is to develop blood and/or urine tests that will help to detect
early signs of rejection in people who have had a liver transplant. Researchers will examine
blood, urine, and tissue samples and try to identify markers for certain conditions such as
rejection, response to therapy, and scarring of the liver. Additionally, researchers would
like to identify biomarkers that can detect damage to the native kidneys before blood levels
of creatinine rises. By studying gene expression, researchers hope to be able to diagnose
these conditions earlier and improve liver survival.

Inclusion Criteria:

- Subjects undergoing primary deceased-donor or living donor liver transplantation.

- Subject must be able to understand and provide informed consent.

Exclusion Criteria:

- Need for combined organ transplantation

- Previous solid organ and/or islet cell transplantation

- Infection with HIV

- Allergy to Iodine

- Inability or unwillingness of a participant to comply with study protocol

- Any condition that, in the opinion of the investigator, would interfere with the
participant's ability to comply with study requirements

We found this trial at

sites

Northwestern University Feinberg School of Medicine

303 E Chicago Ave
Chicago, Illinois 60611

(312) 503-8194